Welcome to our dedicated page for Freenome SEC filings (Ticker: FRNM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Freenome's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Freenome's regulatory disclosures and financial reporting.
Freenome, Inc. (FRNM) reported that Chief Executive Officer and director Elliott Aaron Matthew had 71,920 shares of common stock withheld on September 2, 2026, at $15.25 per share to satisfy tax withholding obligations arising from the vesting of restricted stock units. After this tax-withholding disposition, he holds 345,976 shares of Freenome common stock directly. No Rule 10b5-1 trading plan is reported for this transaction.
Freenome, Inc. (FRNM) has a significant shareholder group led by Roche entities that jointly report beneficial ownership of a large minority stake in the company. Roche Holdings, Inc., Roche Finance Ltd, and Roche Holding Ltd (the “Reporting Persons”) have filed a Schedule 13G disclosing their ownership in Freenome’s common stock.
The Reporting Persons report beneficial ownership of 18,692,766 shares of Freenome common stock, representing 17.4% of the class, based on 107,446,814 shares outstanding as of July 20, 2026. Of these, 18,055,686 shares are held of record by Roche Holdings, Inc. and 637,080 shares are held of record by Roche Finance Ltd. The Reporting Persons state they have 0 shares with sole voting or dispositive power and 18,692,766 shares with shared voting and dispositive power.
Freenome, Inc. (FRNM) filed a resale shelf prospectus on Form S-1/424B3 covering up to 75,188,742 shares of common stock that may be offered from time to time by selling securityholders. The shares comprise PIPE shares, business-combination consideration shares, option and RSU shares, Roche note conversion shares and Private Warrant shares.
Freenome will not receive proceeds from sales by selling securityholders, but may receive up to approximately $36.3 million if options and the Private Warrant are exercised for cash, for general corporate purposes. The company focuses on blood-based multiomics cancer screening, with FDA-approved SimpleScreen CRC, and operates as an emerging growth and smaller reporting company with significant historical losses and substantial R&D, regulatory, competitive, financing, data-privacy, cybersecurity and AI-related risks described in detail in its risk factors.
Freenome, Inc. (FRNM) has filed an S-1 to register up to 75,188,742 shares of common stock for resale by existing holders, including PIPE investors, the SPAC sponsor and initial shareholders, former Freenome Holdings equity holders, option and RSU holders, Roche (via a convertible note conversion) and a private warrant holder. Freenome will not receive proceeds from these secondary sales.
The company may receive up to $36.3 million if all registered options and the private warrant are exercised for cash; shares outstanding were 107,446,814 at the Business Combination closing and would be 112,549,251 assuming full exercise. Freenome is an early cancer detection company focused on blood-based, multiomics tests powered by AI/ML, initially centered on colorectal cancer (CRC). Its SimpleScreen CRC blood test has FDA approval for average‑risk adults 45+, is supported by the PREEMPT CRC study, and will be commercialized in the U.S. by Abbott under an exclusive agreement.
Freenome reports large, ongoing losses as it scales: net losses of $132.6 million for the six months ended June 30 2026, and $219.3 million and $274.4 million for 2025 and 2024, with an accumulated deficit of $1.5 billion. Management believes existing cash, including Business Combination and PIPE proceeds, will fund operations into 2028 but highlights potential future capital needs. The company is an emerging growth company and smaller reporting company, allowing reduced disclosure and delayed adoption of new accounting standards.
Freenome, Inc. received an updated Schedule 13G/A (Amendment No. 2) from ADAR1 Capital Management, LLC, ADAR1 Capital Management GP, LLC, and Daniel Schneeberger regarding Class A Ordinary Shares. The reporting group collectively reports beneficial ownership of 674,695 Class A Ordinary Shares, representing 8.3% of the class, based on 8,157,242 shares outstanding as of June 30, 2026. These shares are held through ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC and other separately managed accounts, with the reporting persons having shared voting and dispositive power and no sole voting or dispositive power.
Highbridge Capital Management, LLC, an investment adviser to certain funds, reports that it currently has no beneficial ownership of Freenome, Inc. common stock, with 0 shares and 0.0% of the class, and no sole or shared voting or dispositive power.
The filing notes that, as of June 30, 2026, Highbridge may have been deemed to beneficially own 661,493 Class A Ordinary Shares of Freenome, representing 8.1% of the Class A Ordinary Shares then outstanding, based on 8,157,242 Class A Ordinary Shares reported outstanding as of June 17, 2026. Highbridge emphasizes that the report should not be construed as an admission that it or related persons are beneficial owners for all purposes.
Freenome, Inc. files an amendment to provide full interim financials and MD&A for Freenome Holdings, Inc. ahead of and around its July 20, 2026 business combination with Perceptive Capital Solutions Corp., which was accounted for as a reverse recapitalization.
For the six months ended June 30, 2026, Freenome generated $6.5 million in revenue, primarily from a major collaboration with Exact Sciences plus U.K. test sales, versus $1.5 million a year earlier. Net loss widened to $132.6 million, with $97.1 million of cash used in operating activities, reflecting heavy R&D and G&A spending.
At June 30, 2026 Freenome reported total assets of $398.5 million, including cash, cash equivalents and short-term marketable securities of about $102.0 million, deferred revenue of $71.1 million tied mainly to the Exact Sciences license, and significant lease and cloud-service commitments. Management states that existing liquidity plus $295.5 million in net proceeds from the SPAC/PIPE transaction is expected to fund operations for at least 12 months from issuance.
Freenome, Inc. received an updated Schedule 13G/A from IPConcept (Luxembourg) S.A. and BIT Global Technology Opportunities SICAV-FIS regarding Class A Ordinary Shares, par value $0.0001 per share, CUSIP G70077105.
Both Luxembourg-based reporting persons state that they now beneficially own 0 shares of this class, representing 0% of the outstanding Class A Ordinary Shares. They report no sole or shared voting power and no sole or shared dispositive power over any Freenome Class A Ordinary Shares, indicating that they no longer hold a reportable position in this security.
Perceptive Capital Solutions Corp received an ownership update from 683 Capital Management, LLC, 683 Capital Partners, LP, and Ari Zweiman. The filing states that these reporting persons do not beneficially own any Class A ordinary shares of the company, resulting in a reported 0 shares and 0% of the class held. The amendment reflects that their holdings have fallen to 5% or less of the class, and all sole and shared voting and dispositive powers are reported as zero. The reporting persons list their principal business address as 1700 Broadway, Suite 4200, New York, New York 10019, and the issuer’s principal executive offices as 51 Astor Place, 10th Floor, New York, New York 10003.